About
Foghorn Therapeutics is a clinical-stage biotechnology company pioneering a new class of medicines designed to modulate the chromatin regulatory system, which functions to orchestrate the genes our cells express — as well as when, where, and in what order.
Using our Gene Traffic Control® proprietary platform, we are rapidly advancing over 10 programs across a wide range of cancers — and aim to explore treatments for other diseases. Our two lead product candidates entered the clinic in 2021.